alexa Bivalent Candidate Vaccine Against HCV And HIV-1: Construction And Biological Evaluation
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

M R Aghasadeghi, M H Pouriayevali, S M Sadat, S D Siadat, M Shafiee Ardestani, F Javadi, R Zabiholahi, M Yousefi, S Hekmat, M S Khosravy and M Davari
Posters: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.021
Objectives: Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections are a global health concern. Therefore, they are considered for the huge number of studies looking for effective vaccines. In the previous study, we introduced a single cycle replicable (SCR) HIV system that, completely maintained the antigenic structures of HIV-1, through its one cycle replicating properties represented a good implication as a potential vaccine candidate, Herein, we constructed a novel HIV-1 virion, capable of expressing non structural 3 (NS3) protein of HCV as potential bivalent candidate vaccine that provides a more immunogenicity, while preventing any pathologic effects with further evaluated its biological properties. Methods: The pIPNL4-3/NS3 containing HIV genome of NL4-3 strain with a 2-kb deletion in reverse transcriptase (RT) and integrase (IN) genes and replacement of the deleted fragment with NS3 was constructed, confirmed by sequencing reactions and transfected into HEK 293T cell line. By further co-transfection of psPAX2 and pMD2.G plasmids, which encoded HIV Gag-pro-pol and vesicular stomatitis virus surface glycoprotein, into the same pIPNL4-3/NS3-harboring cells, pseudotyped virions were produced, evaluated by electron microscopy, quantified using P24 end-point ELISA assay and western blotting. Infectivity of recombinant virions and their efficiency towards the syncytium formation was evaluated on HIV-sensitive MT-2 cells. Results: Production of HIV virions was indicated by the level of P24 protein in culture supernatant of transfected cells and was further confirmed by electron microscopy. Also, expression of NS3 protein was confirmed using western blotting. Formation of syncytia in MT-2 cells also evidenced for the functionality of the surface glycoproteins in produced pseudotyped virions. Interestingly, infectivity analysis verified that the second generation virions were completely non-replicative. Conclusion: The results were shown that a new recombinant virion with capable to express NS3 protein completely maintained the antigenic structures of HIV-1, by its one cycle replicating properties, and represented a good implication as a potential bivalent vaccine candidate. Moreover, this guarantees further investigations toward the assessment of its immunogenicity, which are currently under process. It may also present another interesting approach towards the improvement of its application in bivalent HIV and HCV vaccine researches.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version